Fine Foods & Pharmaceuticals Ntm Logo

Fine Foods & Pharmaceuticals Ntm

Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.

FF | XMIL

Overview

Corporate Details

ISIN(s):
IT0005215329 (+1 more)
LEI:
8156009111DEE8553765
Country:
Italy
Address:
VIA BERLINO, 39 (ZINGONIA), 24040 VERDELLINO
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fine Foods & Pharmaceuticals Ntm is an integrated Contract Sales and Development Manufacturing Organization (CSDMO) that serves as a strategic manufacturing partner for third parties. The company specializes in the development and production of oral solid forms for the pharmaceutical and nutraceutical sectors, as well as products for the cosmetics, medical device, and biocide industries. It leverages over 100 manufacturing lines and a strong focus on scientific innovation, with a significant portion of its workforce dedicated to science and R&D. Fine Foods emphasizes technological excellence, quality, reliability, and a long-standing commitment to ESG principles to support its clients' growth objectives.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-06 11:30
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 29 SETTEMBRE – 3 OTTOBRE 2025…
Italian 444.9 KB
2025-10-02 11:51
Director's Dealing
Allegato 3F / Annex 3F
Italian 28.8 KB
2025-09-29 12:11
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 22 SETTEMBRE – 26 SETTEMBRE 2…
Italian 452.8 KB
2025-09-22 11:05
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 15 SETTEMBRE – 19 SETTEMBRE 2…
Italian 468.2 KB
2025-09-15 12:06
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 8 SETTEMBRE – 12 SETTEMBRE 202…
Italian 458.0 KB
2025-09-10 18:21
Interim Report
Half-year Financial Report as of 30 June 2025
English 2.8 MB
2025-09-08 11:24
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 1 SETTEMBRE – 5 SETTEMBRE 2025…
Italian 476.9 KB
2025-09-02 14:17
Director's Dealing
Allegato 3F / ANNEX 3F
Italian 28.6 KB
2025-08-25 13:01
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 18 AGOSTO – 22 AGOSTO 2025 / …
English 500.7 KB
2025-08-18 12:40
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 11 AGOSTO – 14 AGOSTO 2025 / …
Italian 482.1 KB
2025-08-08 12:38
Transaction in Own Shares
INFORMATIVA SULL’ACQUISTO AZIONI PROPRIE PERIODO 4 AGOSTO – 7 AGOSTO 2025 / TR…
Italian 450.2 KB
2025-08-06 11:22
Report Publication Announcement
Publication Notice – Half-year Financial Report as of 30 June 2025
English 263.9 KB
2025-08-06 11:21
Report Publication Announcement
Avviso di pubblicazione della Relazione Finanziaria semestrale al 30 giugno 2025
Italian 275.2 KB
2025-08-06 11:16
Interim Report
Relazione finanziaria semestrale al 30 giugno 2025
Italian 3.5 MB
2025-08-05 14:29
Earnings Release
Growing revenue Adjusted EBITDA was €21.6 million, +35%, and margins for 16.8%
English 579.2 KB

Automate Your Workflow. Get a real-time feed of all Fine Foods & Pharmaceuticals Ntm filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Fine Foods & Pharmaceuticals Ntm via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Hanmi Pharm. Co., Ltd. Logo
Biopharma firm developing innovative diabetes and cancer drugs for patients and professionals.
South Korea 128940
Hansa Biopharma Logo
Develops antibody-cleaving enzymes to treat rare diseases and enable organ transplants.
Sweden HNSA
HEALIOS K.K. Logo
Develops iPS and somatic stem cell therapies for diseases like ARDS and cancer.
Japan 4593
Heartseed株式会社 Logo
Develops iPSC-derived cell therapies to regenerate heart tissue for heart failure.
Japan 219A
HELLENIC DYNAMICS PLC Logo
Cultivates and supplies THC-dominant medical cannabis for the European pharmaceutical market.
United Kingdom HELD
HEMOGENYX PHARMACEUTICALS PLC Logo
Develops CAR-T therapies for blood cancers, autoimmune disorders, and viral infections.
United Kingdom HEMO
HEM Pharma Inc. Logo
Microbiome biotech using analysis for personalized probiotics, LBPs, and full CDMO services.
South Korea 376270
Hemp Health Spolka Akcyjna Logo
A vertically integrated supplier of medical cannabis raw material for the Polish market.
Poland HMP
Herantis Pharma Oyj Logo
Developing disease-modifying therapies for neurodegenerative conditions like Parkinson's disease.
Finland HRTIS
Global manufacturer of carbapenem antibiotic APIs for regulated markets.
South Korea 106190

Talk to a Data Expert

Have a question? We'll get back to you promptly.